Tom Salemi and I discuss the upcoming DeviceTalks West in Anaheim on October 18 and 19. The DeviceTalks events consistently host conversations with the influential voices of our industry and openly and critically discuss the current and future state of medtech.
J&J, being led by Ashley McEvoy, is making strong moves in divesting themselves of products and platforms that may be better off in someone else’s hands, acquiring flagship companies that are cornerstones of markets that JNJ has not previously played in and empowering them to operate more independently than JNJ had previously operated.
I expect to see JNJ take advantage of the build-to-buy model that is emerging in medtech, as well as joint ventures in digital & robotic areas that JNJ may not have native expertise in but in such partnership bring cash, distribution, and purchasing power to the table that compliments a native core competency of its partners.
See you at DeviceTalks. Tell them I sent ya :).